This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain.
study shows that more and more people are giving up alcohol and pharmaceuticals in favour of cannabis use. The groundbreaking study conducted by New Frontier Data surveyed over 3,000 adult Americans to show people from all age groups and demographics in the U.S. Consumer Profiles. Legalization. appeared first on Leaf Science.
With the growing acceptance and legalization of cannabis, the pharmaceutical industry is taking serious hits, according to a 2022 novel study into the impact of cannabis legalization on pharmaceutical firms. What Is the Pharmaceutical Industry? pharmaceuticals). Still, most pharmaceuticals are heavily processed.
New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Data also demonstrated that none of the biological drugs selected for the comparison study proved to be anti-proliferative to any of the primary cell types assessed.
MoreBetter, creators of the Releaf App, is using this real world data to push back against the claim that there’s no evidence that CBN can help people sleep. In September 2021, MoreBetter hosted a self-reported data collection with this CBN tincture offered to participants for free of charge from CBDistillery. Back to our study.
Just about any industry benefits greatly from the proper use and evaluation of data. The tech giants of today are built mostly on data regarding their users, and advertisers rely on that data to more effectively target their efforts. How to Use the Data. Advantages of Data, Macro, and Micro. RYAH Group Inc.
The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds.
BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. About MyMD Pharmaceuticals, Inc.
We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.
Can businesses cultivate cannabis for pharmaceutical research? The conditions of the relevant licenses and permits. Data Privacy 29. What data privacy obligations do cannabis businesses have? Valid consent for data collection and use. Pharmacies must: Be registered in Australia.
Unlike “pharmaceutical CBD”—which contains zero traces of the psychoactive compound THC (tetrahydrocannabinol) and has been FDA-approved to treat Dravet syndrome and Lennox-Gastaut syndrome —artisanal CBD is non-mechanized and usually contains variable amounts of CBD and THC. It goes by the name of “artisanal CBD.” .
BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. For more information, visit www.mymd.com. About FTSE Russell.
The ERP operates as a system, collecting data in real time and connecting it all together for your. Since the ERP is equipped with all of the company’s information, the access to data is controlled. Since the ERP is equipped with all of the company’s information, the access to data is controlled. Access Control.
SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.
Many mental health disorders have treatment options, but they aren’t nearly as safe and efficacious as conventional pharmaceuticals or therapies. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. Medxtractor Corp.
–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We believe the totality of the data is encouraging and supports advancing to Phase 3. Data Highlights. The condition is caused by inherited mutations in either the TSC1 gene or the TSC2 gene. About Marinus Pharmaceuticals.
The study’s data showed that “Cannabis significantly reduced ratings of depression, anxiety, and stress.” Participants in the study recorded their personal experience when using cannabis for their depression and other mental conditions such as anxiety and stress; scientists were able to use data collected from the app to analyze the results.
The pharmaceutical industry takes a serious economic hit after states legalize marijuana—with an average market loss of nearly $10 billion for drugmakers per each legalization event—according to a first-of-its-kind study. By expanding access and, thus use, legalization could permit cannabis to compete with conventional pharmaceuticals.
Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. Many patients take MMJ for more reasons than one.
Individuals who use cannabis-based medications often want to cure their cancer, not just reduce the symptoms that come with the condition. Work together to weigh the potential benefits and risks specific to your medical condition, and track the progress of your cancer along with your cannabis regimen. 1 So can cannabis cure cancer?
Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.
” Kulfas’ presentation began with some hard data, giving an account of the importance of regulating the activity in Argentina. Why does Argentina have the conditions to be an important producer in the cannabis and hemp industry? ley cáñamo argentina. ley cáñamo argentina. Conversion of the tobacco sector.
–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Chief Executive Officer of Marinus Pharmaceuticals. “We RADNOR, Pa.–(BUSINESS Additionally, improved developmental outcomes may lead to improved patient quality of life.
Marijuana may be a lucrative opportunity on the surface, but there are several conditions that could put the industry out of reach for some time. The production of pharmaceutical-grade cannabis is a highly specialised process — it is not as simple as planting a few marijuana seeds, harvesting the crop and turning it into medicine.”.
Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. Epidyolex has been approved as a treatment option for children as young as two with Lennox-Gastaut syndrome or Dravet syndrome – difficult-to-treat conditions that can cause multiple seizures a day. ” Source BBC: [link].
THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. However, with the database not yet available to the nation’s private clinics there are concerns over the quality and volume of data it will garner.
This differs sharply from the conventional course of cannabis medicine, which is to use whole, clean plant extracts to treat epilepsy and to gradually discontinue use of conventional pharmaceuticals. Another example of cannabinoid mono therapy is the THC pharmaceutical Marinol. The question is, is there truly a difference?
AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. He serves as the primary spokesperson and point of contact with the analyst and investment community and is also responsible for the timely dissemination of information and data to these important stakeholders. About Anebulo Pharmaceuticals, Inc.
It seems like the medical research community remains largely divided on the issue, with some insisting that cannabis use contributes to mental health condition diagnoses while others suggesting that people with mental health conditions are inherently drawn to cannabis use. CBD for Anxiety.
Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis. Sativex was developed by GW Pharmaceuticals, a maker of cannabinoid therapeutics based in Ireland.
As a veteran, being able to get past the PTSD involves transitioning out of the mental and emotional war zone, which is challenging and the reason why veterans seek out multiple methods to deal with the condition. A study conducted by Miriam Reisman reported that between 13.5% What Is The Latest Research for Veterans and PTSD?
In the novel study conducted by researchers at the University of New Mexico, nearly 2,000 people self-administered cannabis over a three-year period and reported their marijuana use via the Releaf App that was specifically designed for the study’s data collection needs. Human reports to date on the subject are largely anecdotal.
Is the focus on the negative impact due to the fact that role players want cannabis to remain illicit as to avoid its potential role in replacing pharmaceutical medication? The data for this graphic was provided by Jim Hudson at Hellth.com. . Scenario 2: Pharmaceuticals. However, the focus of funding remains on negative impacts.
The nearly 3,000 participant study will capture and publish the most comprehensive data ever collected on CBD product effectiveness from 13 commercially available U.S. Radicle ACES is Institutional Review Board (IRB) approved and will capture CBD effectiveness data directly from nearly 3,000 study participants.
RYAH is pleased to contribute RYAH’s IoT devices and data platform and work with Medicann toward perfecting prescribing practices and dosing regimens,” said Gregory Wagner , CEO of RYAH Group, Inc. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation life cycle.
For those who suffer from migraine pain, the excruciating condition can be completely debilitating, impossible to manage without a dark room, a cool cloth over the eyes, and sublime silence. Patients used the app, Strainprint, which allowed data to be archived and studied.
The export to Brazil also confirms the regulatory pathway and acts as a proof of concept in the largest market in South America where we aim to establish long-lasting supply relationships with our Brazilian pharmaceutical partners.”. 1 Source: Passport, Euromonitor International, Cannabis in Latin America, July 2021.
Given the size and scale of the study, RYAH has developed a custom software solution, using OAuth API-integration to protect the privacy of the participants in the study, with the goal of enabling a fully integrated, patient feedback and data collection capability. About RYAH Group, Inc. RYAH Group, Inc.
AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. In compliance with current Good Manufacturing Practice requirements, the Company delivered ANEB-001’s active pharmaceutical ingredient to its contract manufacturer to fill into 10 mg and 50 mg capsules for finished product. About Anebulo Pharmaceuticals, Inc.
The data from the study is expected to be embedded into the RYAH MD platform, with the goal of enabling healthcare professionals to administer THC, CBD and terpenes in milliliters, which are then expected to automatically be converted into milligrams to allow for a customized, targeted patient inhalation session. billion by 2027.
Bipolar disorder is a complex condition that impacts millions worldwide, leading to extreme mood swings, intense emotional episodes, and difficulty managing day-to-day life. Most commonly, pharmaceutical medication is prescribed to regulate moods. But there may be some good news for those coping with this mental health issue.
One of the things she does is collect and analyze data about cannabis products and how patients with different medical conditions respond to them. All of that data is packaged into software doctors can use to manage their patients’ medical marijuana treatment. “I I know how to collect data. I know how to analyze data.
AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. We were able to rapidly incorporate the FDA’s feedback into the design of the current Phase 2 trial to make the data generated in Europe as relevant as possible for a potential future NDA submission. About Anebulo Pharmaceuticals, Inc. Rex Merchant.
With Avicanna’s dedication to quality standards and pharmaceutical positioning we are poised to be a significant long-term player in the European medical market that is predominantly focused on medical utility of cannabinoids and where meeting EU pharmacopeia standards are essential.”.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content